Symbols / TLPH Stock $0.78 -3.00% Talphera, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
TLPH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Vincent J. Angotti
Exch · Country NCM · United States
Market Cap 38.79M
Enterprise Value 24.91M
Income -14.36M
Sales 28.00K
FCF (ttm) -6.53M
Book/sh 0.34
Cash/sh 0.41
Employees 12
Insider 10d —
IPO Feb 11, 2011
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.77
PEG —
P/S 1,385.31
P/B 2.25
P/C —
EV/EBITDA —
EV/Sales 889.52
Quick Ratio 5.35
Current Ratio 5.49
Debt/Eq 38.15
LT Debt/Eq —
EPS (ttm) -0.34
EPS next Y -0.28
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-23
ROA -35.15%
ROE -114.74%
ROIC —
Gross Margin 0.00%
Oper. Margin -481.57%
Profit Margin 0.00%
Shs Outstand 50.05M
Shs Float 24.91M
Insider Own 25.43%
Instit Own 40.74%
Short Float 2.47%
Short Ratio 6.46
Short Interest 1.23M
52W High 1.57
vs 52W High -50.64%
52W Low 0.38
vs 52W Low 103.95%
Beta 0.56
Impl. Vol. 50.00%
Rel Volume 0.24
Avg Volume 196.32K
Volume 48.02K
Target (mean) $3.25
Tgt Median $3.25
Tgt Low $3.00
Tgt High $3.50
# Analysts 2
Recom None
Prev Close $0.80
Price $0.78
Change -3.00%
About

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.25
Mean price target
2. Current target
$0.78
Latest analyst target
3. DCF / Fair value
$-2.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.78
Low
$3.00
High
$3.50
Mean
$3.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-01 reit HC Wainwright & Co. Buy → Buy $6
2025-01-21 reit HC Wainwright & Co. Buy → Buy $6
2024-08-16 reit HC Wainwright & Co. Buy → Buy $6
2024-05-15 reit HC Wainwright & Co. Buy → Buy $6
2024-05-06 init Maxim Group — → Buy $3
2024-03-07 reit HC Wainwright & Co. Buy → Buy $6
2024-01-22 main HC Wainwright & Co. Buy → Buy $6
2023-12-07 reit HC Wainwright & Co. Buy → Buy $5
2023-10-02 init Alliance Global Partners — → Buy $4
2023-09-25 main HC Wainwright & Co. Buy → Buy $5
2023-08-18 up HC Wainwright & Co. Neutral → Buy $8
News
RSS: Latest TLPH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 ANGOTTI VINCENT J Chief Executive Officer — 213,310 $0.80 $169,965
2026-02-12 ANGOTTI VINCENT J Chief Executive Officer — 105,364 $0.81 $85,587
2026-02-12 DASU BADRI N Officer — 35,000 $0.81 $28,430
2026-02-12 ASADORIAN RAFFI Chief Financial Officer — 45,000 $0.81 $36,554
2026-02-12 ASLAM SHAKIL Officer — 35,000 $0.81 $28,430
2025-10-23 WAN MARK ALLEN Director — 4,267 $0.00 $0
2025-10-23 HOFFMAN STEPHEN J. M.D., PH.D. Director — 4,267 $0.00 $0
2025-10-23 ADAMS ADRIAN Director — 4,267 $0.00 $0
2025-10-23 BROADFOOT JILL MARIE Director — 4,267 $0.00 $0
2025-10-23 BOZILENKO MARINA Director — 4,267 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.03
0.00
-100.00%
0.65
0.00
Operating Revenue
0.03
0.00
-100.00%
0.65
0.00
Cost Of Revenue
—
—
—
2.59
Reconciled Cost Of Revenue
—
—
—
2.59
Gross Profit
—
—
—
-0.82
Operating Expense
13.51
-11.41%
15.25
-13.04%
17.54
-13.82%
20.35
Research And Development
6.03
-10.20%
6.72
+21.13%
5.55
+66.00%
3.34
Selling General And Administration
7.48
-12.36%
8.53
-28.85%
11.99
-29.49%
17.01
Total Expenses
13.51
-11.41%
15.25
-13.04%
17.54
-13.82%
20.35
Operating Income
-13.48
+11.59%
-15.25
+9.69%
-16.89
+17.02%
-20.35
Total Operating Income As Reported
-13.48
+11.59%
-15.25
+9.69%
-16.89
+33.25%
-25.30
EBITDA
-14.36
-13.90%
-12.61
-28.12%
-9.84
-115.90%
61.90
Normalized EBITDA
-13.05
+10.46%
-14.57
+3.88%
-15.16
+11.86%
-17.20
Reconciled Depreciation
—
0.00
-100.00%
0.31
-81.12%
1.65
EBIT
-14.36
-13.90%
-12.61
-24.20%
-10.15
-116.85%
60.25
Total Unusual Items
-1.31
-166.99%
1.96
-63.10%
5.32
-93.27%
79.10
Total Unusual Items Excluding Goodwill
-1.31
-166.99%
1.96
-63.10%
5.32
-93.27%
79.10
Special Income Charges
—
—
0.00
-100.00%
79.10
Other Special Charges
—
—
—
-84.05
Impairment Of Capital Assets
—
—
0.00
-100.00%
4.95
Net Income
-14.29
-9.89%
-13.00
+29.31%
-18.40
-138.52%
47.76
Pretax Income
-14.36
-10.45%
-13.00
-26.41%
-10.29
-117.39%
59.14
Net Non Operating Interest Income Expense
0.44
+52.98%
0.28
-77.77%
1.28
+232.12%
0.39
Interest Expense Non Operating
0.00
-100.00%
0.39
+194.03%
0.13
-87.99%
1.12
Net Interest Income
0.44
+52.98%
0.28
-77.77%
1.28
+232.12%
0.39
Interest Expense
0.00
-100.00%
0.39
+194.03%
0.13
-87.99%
1.12
Interest Income Non Operating
0.44
-35.79%
0.68
-52.05%
1.42
-5.73%
1.50
Interest Income
0.44
-35.79%
0.68
-52.05%
1.42
-5.73%
1.50
Other Income Expense
-1.31
-166.99%
1.96
-63.10%
5.32
-93.27%
79.10
Other Non Operating Income Expenses
—
—
—
84.05
Gain On Sale Of Security
-1.31
-166.99%
1.96
-63.10%
5.32
—
Tax Provision
—
—
0.00
-100.00%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
-100.00%
0.02
Net Income Including Noncontrolling Interests
-14.29
-9.89%
-13.00
+29.31%
-18.40
-138.52%
47.76
Net Income From Continuing Operation Net Minority Interest
-14.36
-10.45%
-13.00
-26.41%
-10.29
-117.40%
59.12
Net Income From Continuing And Discontinued Operation
-14.29
-9.89%
-13.00
+29.31%
-18.40
-138.52%
47.76
Net Income Continuous Operations
-14.36
-10.45%
-13.00
-26.41%
-10.29
-117.40%
59.12
Net Income Discontinuous Operations
0.07
0.00
+100.00%
-8.11
+28.67%
-11.37
Normalized Income
-13.05
+12.82%
-14.97
+4.10%
-15.61
+21.81%
-19.96
Net Income Common Stockholders
-14.29
-9.89%
-13.00
+29.31%
-18.40
-143.46%
42.33
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
5.24
Diluted EPS
-0.34
+32.00%
-0.50
+61.24%
-1.29
-122.55%
5.72
Basic EPS
-0.34
+32.00%
-0.50
+61.24%
-1.29
-122.51%
5.73
Basic Average Shares
42.41
+64.09%
25.85
+81.20%
14.26
+93.14%
7.39
Diluted Average Shares
42.41
+64.09%
25.85
+81.20%
14.26
+92.57%
7.41
Diluted NI Availto Com Stockholders
-14.29
-9.89%
-13.00
+29.31%
-18.40
-143.45%
42.34
Preferred Stock Dividends
—
—
—
0.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
29.72
+62.97%
18.24
-10.59%
20.39
-57.05%
47.49
Current Assets
20.90
+121.94%
9.42
-18.65%
11.58
-52.88%
24.57
Cash Cash Equivalents And Short Term Investments
20.38
+129.96%
8.86
-5.52%
9.38
-40.51%
15.77
Cash And Cash Equivalents
5.89
-33.50%
8.86
+54.92%
5.72
-62.55%
15.28
Cash Equivalents
5.48
-35.52%
8.50
+94.09%
4.38
—
Cash Financial
0.41
+13.74%
0.36
-72.88%
1.34
—
Other Short Term Investments
14.49
0.00
-100.00%
3.66
+639.39%
0.49
Receivables
—
—
—
0.31
Accounts Receivable
—
—
—
0.31
Inventory
—
—
—
1.18
Raw Materials
—
—
—
0.80
Work In Process
—
—
—
0.34
Finished Goods
—
—
—
0.04
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
0.00
-100.00%
5.00
Assets Held For Sale Current
—
—
0.00
-100.00%
1.93
Other Current Assets
0.52
-6.32%
0.55
-74.76%
2.19
+17.69%
1.86
Total Non Current Assets
8.82
+0.00%
8.82
+0.00%
8.82
-61.52%
22.92
Net PPE
—
—
—
13.86
Gross PPE
—
—
—
25.45
Accumulated Depreciation
—
—
—
-11.59
Properties
—
—
—
0.00
Machinery Furniture Equipment
—
—
—
1.81
Construction In Progress
—
—
—
8.98
Other Properties
—
—
—
8.82
Leases
—
—
—
5.84
Goodwill And Other Intangible Assets
8.82
+0.00%
8.82
+0.00%
8.82
+0.00%
8.82
Other Intangible Assets
8.82
+0.00%
8.82
+0.00%
8.82
+0.00%
8.82
Other Non Current Assets
—
—
0.02
-99.86%
14.10
Total Liabilities Net Minority Interest
12.68
+23.93%
10.23
+62.72%
6.29
-75.50%
25.67
Current Liabilities
3.81
+43.90%
2.65
-41.33%
4.51
-67.23%
13.77
Payables And Accrued Expenses
1.77
+69.25%
1.04
-41.22%
1.78
-13.58%
2.06
Payables
0.54
-18.81%
0.67
-49.85%
1.34
+6.37%
1.26
Accounts Payable
0.54
-18.81%
0.67
-49.85%
1.34
+6.37%
1.26
Current Accrued Expenses
1.22
+227.01%
0.37
-15.00%
0.44
-44.93%
0.80
Pensionand Other Post Retirement Benefit Plans Current
1.39
+58.18%
0.88
-56.11%
2.00
+15.76%
1.73
Current Debt And Capital Lease Obligation
—
—
—
5.36
Current Debt
—
—
—
5.36
Other Current Borrowings
—
—
—
5.76
Current Capital Lease Obligation
—
—
—
1.70
Current Deferred Liabilities
—
—
—
0.12
Current Deferred Revenue
—
—
—
0.12
Other Current Liabilities
0.65
-10.10%
0.72
-1.09%
0.73
-84.18%
4.62
Total Non Current Liabilities Net Minority Interest
8.88
+16.96%
7.59
+326.77%
1.78
-85.06%
11.90
Liabilities Heldfor Sale Non Current
—
—
0.00
-100.00%
4.00
Long Term Debt And Capital Lease Obligation
—
—
—
2.96
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
—
—
—
2.96
Non Current Deferred Liabilities
—
—
—
1.04
Non Current Deferred Revenue
—
—
—
1.04
Other Non Current Liabilities
6.50
-0.43%
6.53
—
0.81
Stockholders Equity
17.04
+112.91%
8.00
-43.28%
14.11
-35.34%
21.81
Common Stock Equity
17.04
+112.91%
8.00
-43.28%
14.11
-35.34%
21.81
Capital Stock
0.05
+188.24%
0.02
+0.00%
0.02
+112.50%
0.01
Common Stock
0.05
+188.24%
0.02
+0.00%
0.02
+112.50%
0.01
Share Issued
49.33
+189.66%
17.03
+0.45%
16.95
+105.64%
8.24
Ordinary Shares Number
49.33
+189.66%
17.03
+0.45%
16.95
+105.64%
8.24
Additional Paid In Capital
488.51
+5.01%
465.21
+1.51%
458.31
+2.39%
447.63
Retained Earnings
-471.52
-3.13%
-457.23
-2.93%
-444.23
-4.32%
-425.83
Total Equity Gross Minority Interest
17.04
+112.91%
8.00
-43.28%
14.11
-35.34%
21.81
Total Capitalization
17.04
+112.91%
8.00
-43.28%
14.11
-35.34%
21.81
Working Capital
17.09
+152.45%
6.77
-4.16%
7.06
-34.57%
10.80
Invested Capital
17.04
+112.91%
8.00
-43.28%
14.11
-48.10%
27.18
Total Debt
—
—
—
5.36
Net Debt
—
—
—
—
Capital Lease Obligations
—
—
—
4.66
Net Tangible Assets
8.22
+1104.40%
-0.82
-115.47%
5.29
-59.32%
12.99
Tangible Book Value
8.22
+1104.40%
-0.82
-115.47%
5.29
-59.32%
12.99
Current Notes Payable
—
—
—
5.76
Derivative Product Liabilities
2.38
+123.94%
1.06
-40.33%
1.78
-74.95%
7.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-11.36
+10.40%
-12.68
+27.49%
-17.49
+38.26%
-28.33
Cash Flow From Continuing Operating Activities
-11.36
+10.40%
-12.68
+27.49%
-17.49
+38.26%
-28.33
Net Income From Continuing Operations
-14.29
-9.89%
-13.00
+29.31%
-18.40
-138.52%
47.76
Depreciation Amortization Depletion
—
0.00
-100.00%
0.31
-81.12%
1.65
Depreciation And Amortization
—
0.00
-100.00%
0.31
-81.12%
1.65
Other Non Cash Items
-0.03
-107.11%
0.39
+122.29%
-1.77
+97.92%
-84.95
Stock Based Compensation
0.70
-29.32%
0.99
-42.80%
1.73
-40.15%
2.89
Asset Impairment Charge
—
0.00
-100.00%
7.92
+60.02%
4.95
Operating Gains Losses
1.31
+283.40%
-0.72
+87.47%
-5.72
-838.06%
0.78
Gain Loss On Investment Securities
1.31
+283.40%
-0.72
+86.52%
-5.32
-786.45%
0.78
Change In Working Capital
1.08
+583.04%
-0.22
+85.46%
-1.54
-10.86%
-1.39
Change In Receivables
—
—
-0.19
-26.85%
-0.15
Changes In Account Receivables
—
—
-0.19
-26.85%
-0.15
Change In Inventory
—
0.00
-100.00%
0.06
+157.01%
-0.11
Change In Prepaid Assets
0.04
-97.87%
1.64
+483.99%
0.28
-6.02%
0.30
Change In Payables And Accrued Expense
1.05
+156.14%
-1.86
-9.26%
-1.71
-60.73%
-1.06
Change In Accrued Expense
1.25
+205.11%
-1.19
-5.48%
-1.13
+29.82%
-1.61
Change In Payable
-0.21
+69.00%
-0.67
-16.70%
-0.57
-204.36%
0.55
Change In Account Payable
-0.21
+69.00%
-0.67
-16.70%
-0.57
-204.36%
0.55
Change In Other Working Capital
—
—
-0.03
+66.28%
-0.09
Change In Other Current Assets
—
—
0.23
0.00
Change In Other Current Liabilities
—
0.00
+100.00%
-0.15
+48.42%
-0.28
Investing Cash Flow
-14.35
-479.40%
3.78
+816.10%
-0.53
-101.45%
36.45
Cash Flow From Continuing Investing Activities
-14.35
-479.40%
3.78
+816.10%
-0.53
-101.45%
36.45
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.10
+72.53%
-0.36
Purchase Of PPE
—
0.00
+100.00%
-0.10
+72.53%
-0.36
Capital Expenditure
—
—
-0.10
+72.53%
-0.36
Net Investment Purchase And Sale
-14.35
-479.40%
3.78
+219.99%
-3.15
-108.18%
38.50
Purchase Of Investment
-17.82
-257.80%
-4.98
-36.37%
-3.65
+53.56%
-7.86
Sale Of Investment
3.47
-60.39%
8.76
+1652.00%
0.50
-98.92%
46.36
Net Other Investing Changes
—
—
2.72
+261.41%
-1.69
Financing Cash Flow
22.74
+88.81%
12.04
+247.49%
3.47
+783.63%
-0.51
Cash Flow From Continuing Financing Activities
22.74
+88.81%
12.04
+247.49%
3.47
+783.63%
-0.51
Net Issuance Payments Of Debt
—
0.00
+100.00%
-5.42
+35.78%
-8.43
Repayment Of Debt
—
0.00
+100.00%
-5.42
+35.78%
-8.43
Long Term Debt Payments
—
0.00
+100.00%
-5.42
+35.78%
-8.43
Net Long Term Debt Issuance
—
0.00
+100.00%
-5.42
+35.78%
-8.43
Net Common Stock Issuance
—
0.00
-100.00%
8.86
+10.89%
7.99
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-0.32
Proceeds From Stock Option Exercised
22.74
+284.71%
5.91
+22634.62%
0.03
-64.86%
0.07
Net Other Financing Charges
—
6.13
+27977.27%
-0.02
+62.07%
-0.06
Changes In Cash
-2.97
-194.49%
3.14
+121.59%
-14.55
-291.20%
7.61
Beginning Cash Position
8.86
+54.92%
5.72
-71.78%
20.27
+60.11%
12.66
End Cash Position
5.89
-33.50%
8.86
+54.92%
5.72
-71.78%
20.27
Free Cash Flow
-11.36
+10.40%
-12.68
+27.90%
-17.59
+38.69%
-28.70
Interest Paid Supplemental Data
—
0.00
-100.00%
0.12
-85.78%
0.84
Amortization Of Securities
-0.14
-17.36%
-0.12
-404.17%
-0.02
—
Common Stock Issuance
—
0.00
-100.00%
8.86
+10.89%
7.99
Issuance Of Capital Stock
—
0.00
-100.00%
8.86
+7.67%
8.22
Net Preferred Stock Issuance
—
—
0.00
+100.00%
-0.08
Preferred Stock Issuance
—
—
0.00
-100.00%
0.24
Preferred Stock Payments
—
—
0.00
+100.00%
-0.32
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category